U.S. Basic Materials Stock News

Federal National Mortgage Association (FNMA) is attracting fresh attention as reports suggest it could soon emerge from government conservatorship. Investors are considering how this long-anticipated move might affect both common and preferred shares. See our latest analysis for Federal National Mortgage Association. Fannie Mae has not only drawn renewed investor attention over its possible exit from conservatorship, but has also seen sizable share price swings this year. After a meteoric...

If you’ve been watching Roblox lately and wondering whether it’s the right moment to buy, sell, or just hold tight, you’re not alone. Investors everywhere are buzzing about its sharp rise this year. Roblox stock has climbed 125.9% year-to-date and an impressive 232.9% over the past twelve months. Even after some short-term turbulence, like the recent 1.8% dip in the past month, the long-term story has been about notable growth. So, what’s behind all these swings? Part of it is Roblox’s unique...

Thinking about what to do with Atlassian stock right now? You’re not alone. It’s the kind of company that tends to get people talking, especially after the wild ride its shares have taken lately. Just over the past week, Atlassian bounced back by 5.1%, hinting at renewed optimism. However, when you look over a month, the picture gets cloudier, with the stock down nearly 12%. Year-to-date, it has been a rougher journey, with shares off by 37.3%. The longer-term charts show a similar pattern,...

Earlier this week, Davenport & Co LLC disclosed it had sold 15,100 shares of Kinsale Capital Group, valued at approximately US$6.84 million, reducing its total holdings to 519,906 shares. The transaction appears to align with general portfolio management practices rather than signal any change in outlook for Kinsale Capital Group. With Kinsale's next earnings report imminent, we'll explore how this upcoming disclosure and Davenport's activity may shape the investment outlook. Explore 26 top...

In October 2025, Gilead Sciences presented significant advances at the European AIDS Conference and ESMO Congress, unveiling new HIV treatment data, progress in long-acting therapies, and promising results for its oncology pipeline, including Trodelvy in metastatic triple-negative breast cancer. An important highlight was the settlement that extends exclusivity for Gilead’s key HIV drug Biktarvy until April 2036, reinforcing the company's leadership and supporting the commercial longevity of...

Webull (BULL) shares have quietly trended lower this month, with the stock down 14% over the past month and 35% over the past 3 months. Investors may be taking a closer look at the company’s fundamentals and recent performance. See our latest analysis for Webull. After a tough few months, Webull’s 30-day share price return of -13.6% and 90-day return of -34.8% underscore fading momentum. Even so, its three-year total shareholder return is still positive. Steep recent drops suggest investors...

Cadence Design Systems (CDNS) drew attention at the recent OCP Global Summit by partnering with Alcor Micro and Jmem Tek to unveil digital twin design solutions for AI and high-performance computing servers. Investors are taking notice because this industry collaboration highlights Cadence’s role in next-generation chip integration. See our latest analysis for Cadence Design Systems. Recent momentum for Cadence Design Systems reflects growing attention on its partnerships and digital twin...

Guardant Health, Inc. announced that data spanning 15 accepted abstracts from its oncology portfolio were presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, covering key innovations in blood-based cancer detection, monitoring, and tumor profiling across multiple cancer types. New findings showcased the clinical utility of Guardant’s Infinity and Reveal technologies for molecular tumor subtyping and therapy response monitoring, highlighting the company’s...

RXO (RXO) is facing fresh scrutiny after a shareholder rights law firm began investigating whether company leadership misled investors or omitted key details. This comes as concerns mount about the company’s slipping profitability and rising costs. See our latest analysis for RXO. RXO’s share price has trended down most of this year, and the latest legal worries have only reinforced the negative momentum. With a 1-year total shareholder return of -40.98% and a year-to-date share price return...

Xencor (XNCR) shares have moved nearly 60% higher over the past month, catching the attention of investors interested in biotechnology stocks with a turnaround story. Despite this rally, the stock remains well below year-ago levels. This creates a nuanced setup for those watching its next move. See our latest analysis for Xencor. Xencor’s recent surge comes after a tough run. Last month’s 59.7% share price return stands out sharply from the much weaker trend over the past year. Even with...

ASML Holding (NasdaqGS:ASML) stock has seen a steady climb lately. This movement has drawn attention as investors look for growth opportunities in the semiconductor space. In the past month, shares are up around 18%. See our latest analysis for ASML Holding. Momentum is clearly building for ASML Holding, with the stock notching an impressive 18% one-month share price return and riding a wave of upbeat sentiment among semiconductor names this year. Over the longer term, investors have...

In recent days, Tenet Healthcare has received multiple analyst upgrades and raised ratings from major financial institutions, signaling increased industry optimism about the company's outlook and performance. This heightened analyst confidence comes at a time when the company is actively investing in expanding its healthcare footprint and operational capabilities across the United States. We’ll examine how the wave of analyst upgrades underscores investor confidence in Tenet Healthcare’s...

Mobileye Global (MBLY) shares have slipped about 3% after a recent stretch of weaker returns. Investors may be wondering if current levels, now almost 30% lower for the year, present an interesting entry point for the stock. See our latest analysis for Mobileye Global. Mobileye’s nearly 30% share price decline year-to-date reflects shifting investor sentiment, despite its impressive 1-year total shareholder return of almost 10%. Momentum has cooled recently, with the stock’s valuation coming...

On October 7, 2025, Goldman Sachs analyst Mikhail Butkov upgraded Joint Stock Company Kaspi.kz (NASDAQ:KSPI) to Buy, highlighting the company’s attractive valuation after a year of regulatory and interest rate challenges. This upgrade draws investor attention to Kaspi.kz’s upcoming third-quarter earnings call on November 10, 2025, where the market looks for further insights into the company’s future outlook. We’ll explore how Goldman Sachs’ recognition of Kaspi.kz’s perceived undervaluation...

In recent days, uniQure N.V. has drawn increased investor attention due to a high short interest of 17.91% and recognition from Seeking Alpha's Quant metrics with a strong "Buy" rating of 4.99. The company’s partnership with Bristol Myers Squibb continues to advance its cardiovascular gene therapy pipeline, highlighting progress in a cutting-edge area of biotechnology. The elevated short interest reflects heightened market scrutiny, while the collaboration underscores the industry’s growing...

Interactive Brokers Group (IBKR) reported a 31.4% increase in earnings over the past year, well ahead of its five-year average annual growth of 29.8%. Net profit margins also improved to 15.4%, rising from last year’s 14.1%, underscoring the company’s consistently high-quality earnings. With analysts forecasting annual revenue growth of 4.1% and projected EPS growth of 10.08% moving forward, the numbers show that profitability is still the company’s highlight. However, expectations for future...

If you have Permian Resources on your watchlist, or you already own shares, you are probably wondering what is next after a rocky few weeks. The stock has slid about 9.4% over the past month and is down 17.3% since the start of the year. However, you might notice it is impressively up over 1,900% in the last five years. That kind of history makes anyone question whether the price resets offer a real opportunity or if renewed caution is needed. Market sentiment around energy stocks has shifted...

In recent news, investment managers highlighted that Ameriprise Financial faced temporary headwinds during the quarter, citing equity market volatility, institutional outflows in its asset management business, and slower flows in Advice Wealth Management as weighing on recent performance despite record client assets at US$1.6 trillion. Ameriprise has also been recognized by J.D. Power for outstanding customer service and continues to advance strategic initiatives, such as adviser technology...

PT Pipa Mas Putih recently announced a partnership with 3M to produce high-resistance Ceramic Sand Screens in Indonesia, aiming to enhance efficiency and reliability for high-pressure wells and excessive sand production environments. This collaboration channels 3M's global expertise and Indonesia's manufacturing capabilities to accelerate delivery timelines, support local innovation, and contribute to energy resilience in the region. We'll explore how 3M's focus on innovation and new...

Zenas BioPharma (ZBIO) jumped into the spotlight following news of a multi-billion dollar global licensing agreement with InnoCare Pharma. The deal expands its pipeline to cover multiple autoimmune product candidates, including a late-stage therapy for multiple sclerosis. See our latest analysis for Zenas BioPharma. Several high-profile events have kept Zenas BioPharma in the headlines, including insider and institutional share purchases, equity offerings, and a headline-grabbing licensing...

Vera Therapeutics announced that data from the Phase 3 ORIGIN trial of its lead drug atacicept for IgA nephropathy will be featured in a late-breaking oral presentation at ASN Kidney Week 2025, with additional data from the ORIGIN Extend and PIONEER trials also on display. Atacicept has received FDA Breakthrough Therapy Designation, positioning it as a promising potential new therapy for rare kidney diseases based on its clinically meaningful trial results and planned regulatory...

If you are trying to decide whether to hold, buy, or simply keep an eye on Amazon.com, you are definitely not alone. Few stocks generate as much buzz and debate, especially after the kind of price action we have seen lately. Amazon’s shares, most recently closing at $213.04, have pulled back about 8.0% in the past month and remain slightly down at -3.3% year-to-date. This comes despite a robust 12.7% gain over the past year and a remarkable 78.5% jump over three years. That roller-coaster...

Recent analyst updates have put Hudson Pacific Properties (HPP) back in the spotlight, as Wells Fargo maintained its Buy rating and several others issued supportive recommendations. This growing consensus is sparking fresh interest among investors. See our latest analysis for Hudson Pacific Properties. Hudson Pacific Properties saw renewed interest this week as upbeat analyst commentary followed solid quarterly results and a modest 3.2% 7-day share price gain. Despite these encouraging...

Walt Disney (DIS) shares have been moving within a fairly narrow range, with modest gains over the past week and a slight dip this month. Investors are keeping an eye on recent performance as the market digests the company's latest numbers. See our latest analysis for Walt Disney. Disney’s share price has edged lower over the past month; however, the company’s one-year total shareholder return of nearly 15% signals solid momentum is still in play, especially when compared to its broader...